SILVER SPRING
BESREMi cleared for essential thrombocythemia in adults
- Sponsor
- PharmaEssentia Corporation $6446
- Drug
- BESREMi · ropeginterferon alfa-2b-njft
- Indication
- Essential thrombocythemia in adults
FDA approves ropeginterferon alfa-2b-njft for the treatment of adults with essential thrombocythemia.
What this means
Besremi is a type of injected interferon therapy that helps regulate the production of blood cells. Today the FDA approved the drug to treat adults with essential thrombocythemia, a condition where the body makes too many platelets. This expands the treatment options for patients with this blood disease.
Drug Watch — recent news on BESREMi
- 5 Notable FDA Approvals From the First Half of September - American Journal of Managed Care
- Targeting inflammation may help control polycythemia vera - Rare Cancer News
- First Approval for Rare Blood Cancer in Nearly 30 Years - American Association for Cancer Research (AACR)
- PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - Business Wire
- Start With FIRST-LINE BESREMi Pen for Patients With PV Requiring Cytoreductive Therapy: From Clinical Results to Real-World Practice - HMP Global Learning Network